文献速递临床试验与 GCP流行病学与生物统计

保护海马的全脑放疗治疗同步脑转移对比序贯脑转移瘤加量全脑放疗治疗小细胞肺癌脑转移的随机对照试验研究方案

Comparison of whole brain radiation therapy for synchronous brain metastases with irradiation protecting the hippocampus versus whole brain radiotherapy for sequential brain metastases to boost irradiation in the treatment of brain metastases from SCLC: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2022-10-14

本研究为随机对照前瞻性试验,纳入102例小细胞肺癌脑转移患者,按1:1随机分为保护海马的全脑放疗组(同步脑转移)和序贯脑转移瘤加量全脑放疗组。主要结局为颅内无进展生存时间,次要结局包括神经功能、生活质量和总生存率,每2个月随访一次,旨在为优化预后治疗方案提供临床证据。

要点

  • 纳入102例小细胞肺癌脑转移患者,1:1随机分组
  • 试验组为保护海马的全脑放疗治疗同步脑转移,对照组为序贯脑转移瘤加量全脑放疗
  • 主要结局为颅内无进展生存时间,次要结局包括神经功能、生活质量和总生存率

核心结论

  • 研究旨在评估保护海马的全脑放疗治疗同步脑转移对比序贯脑转移瘤加量全脑放疗在小细胞肺癌脑转移患者中的疗效与安全性,为该治疗提供高质量临床证据,此前未见报道。

研究设计与样本

  • 随机、对照、前瞻性研究,纳入102例小细胞肺癌脑转移患者,按1:1随机分为试验组(保护海马的全脑放疗治疗同步脑转移)和对照组(序贯脑转移瘤加量全脑放疗)。
  • 样本量通过单侧检验计算,102例参与者为使主要结果具有统计学和临床意义所需。
  • 随访每2个月进行一次,最后一名患者完成随访后使用SPSS软件进行数据分析。
  • 方案版本1.0于2021年1月1日实施;招募于2021年4月1日开始,将于2024年3月31日结束。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study is in regard to the comparison of whole brain radiation therapy for synchronous brain metastases with irradiation protecting the hippocampus versus whole brain radiotherapy for sequential brain metastases to boost irradiation in the treatment of brain metastases from small cell lung cancer (SCLC). Therapeutically, they have notably varying dose distributions. Based on theoretical and model studies, it has long been speculated that these modes may result in different prognostic outcomes. We aim to assess the efficacy of tomotherapy in the treatment of SCLC brain metastases while protecting the key functional area, the hippocampus, and minimizing any neurocognitive impairments incurred by radiation. METHODS: This is a randomized, controlled, prospective study including 102 SCLC patients with brain metastases randomized (1:1) to the experimental (whole brain radiation therapy for synchronous brain metastases with irradiation to protect the hippocampus) or control (whole brain radiotherapy for sequential brain metastases to boost irradiation) group. The sample size is calculated through a single-sided test; 102 participants will be required for the main results to have statistical and clinical significance. We aim to provide clinical trial data support for better prognostic treatment options in patients with SCLC and brain metastases. The clinical trial data include both the primary and secondary outcomes; the primary outcome is the intracranial progression-free survival time after the new technology application. The secondary study outcomes include the assessment of neurological function, the quality of life, and the overall survival rate. Follow-up consultations will be conducted every 2 months. After the final patient completes follow-up, the Statistical Product and Service Solutions software will be used for scientific and rigorous data analysis. Version 1.0 of the protocol was implemented on January 1, 2021; the recruitment process for this clinical trial commenced on April 1, 2021, and will end on March 31, 2024. DISCUSSION: The study will provide high-quality clinical evidence to support the efficacy and safety of whole brain radiation therapy for synchronous brain metastases with dose irradiation protecting the hippocampus versus whole brain radiotherapy for sequential brain metastases with push volume irradiation for the treatment of patients who have lung cancer as well as brain metastases. This has not been previously reported. TRIAL REGISTRATION: This trial is registered with the Chinese Clinical Trial Registry (ChiCTR1900027539; November 17, 2019) (URL: https://www.chictr.org.cn/hvshowproject.aspx?id=20515 ).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zhang X, Wang T, Wang CY, et al. Comparison of whole brain radiation therapy for synchronous brain metastases with irradiation protecting the hippocampus versus whole brain radiotherapy for sequential brain metastases to boost irradiation in the treatment of brain metastases from SCLC: study protocol for a randomized controlled trial. Trials. 2022. PMID: 36242060. doi:10.1186/s13063-022-06826-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。